Three-drug obesity therapy improved blood fat particle profiles
A 26-week randomized trial in adults with obesity but without type 2 diabetes found favorable changes in cholesterol-carrying particles with the three-drug combination.
Our read
Interventions- Studied:
- Randomized trial in adults with obesity but without type 2 diabetes, against semaglutide alone (Double-blind, placebo-controlled, registered NCT06299098)
- What changed:
- Total and small low-density lipoprotein particles decreased, more evident in men receiving all three drugs
- The catch:
- Blood fat measurements are surrogate markers; heart disease was not measured
- In the record:
- The 5th paper on triple therapy with results in people; 10 on record in all.
Editor of record: Boris Djordjevic · AgingResearch.News
Adults with obesity but without type 2 diabetes received semaglutide alone or with trevogrumab, with or without garetosmab, in a 26-week randomized, double-blind trial. Semaglutide was increased to 2.4 milligrams by weekly injection. Trevogrumab injections delivered 200 or 400 milligrams weekly; the higher dose could include garetosmab at 10 milligrams per kilogram intravenously every four weeks.
Blood tests found decreases in total and small low-density lipoprotein particles, which carry cholesterol, more evident in men receiving all three drugs. Large high-density lipoprotein particles, another cholesterol-carrying type, increased across treatment groups. Except for triglycerides, a type of blood fat, adding trevogrumab with or without garetosmab did not further improve conventional blood fat measurements compared with semaglutide alone.
Why it matters
Blood fat particle composition is relevant to cardiovascular disease, a concern in later life. The findings bear on the broader heart and metabolic effects of obesity treatment.
Caveats
Changes in blood measurements do not establish a benefit against heart disease. The conference abstract did not report participant numbers or adverse events, and the trial excluded people with type 2 diabetes.
The paper
Inc.
AHA Scientific Sessions 2026 Abstract, Nov 2, 2026
Presented at AHA Scientific Sessions 2026, abstract 6370
Comments
Be the first to comment.